GNI Ltd.

Shinjuku, Japan
Shinjuku, Japan

Time filter

Source Type

News Article | May 8, 2017
Site: www.theguardian.com

Poverty reduction in the world’s poorest countries risks being diluted by the government’s increasing tendency to devote a bigger slice of Britain’s aid budget to pursuing the national interest, the Institute for Fiscal Studies has warned. The thinktank estimated that overseas development assistance would rise by £1bn during the course of the next parliament as a result of Theresa May’s pledge to continue meeting the United Nations 0.7% aid target. But it said that in recent years less of ODA spending was being channeled through the Department for International Development, with a growing emphasis on ensuring UK firms benefited. In a pre-election analysis, the IFS said Britain’s spending on aid had almost doubled since Tony Blair promised to meet the UN target at the Gleneagles summit in July 2005. Spending had risen in inflation-adjusted terms from £7.4bn to £13.6bn in 2016 and was on course to reach almost £15bn by 2021. Cross-party adherence to the 2005 promise meant that DfID was spared the austerity that affected most government departments after the Conservative-Liberal Democrat coalition came to power in 2010, the IFS said. DfID’s budget had risen by 24% between 2010-11 and 2015-16, while the average cuts for departments outside of the NHS, education and defence were 28%. But the IFS said there had been a change of emphasis since 2015, with more than a quarter of the aid budget now being spent outside DFID in 2016 up from 14% two years earlier. “So far Theresa May has made it clear that if she wins the election she will uphold the UK’s commitment to spending 0.7% of GNI [gross national income] on ODA”, the IFS report said. “However, across the main parties, there has been little indication of how this money will be spent and what balance they will aim to strike between national interest and global poverty alleviation goals in UK aid spending going forward.” May has been under pressure from some of her own MPs and from Conservative-supporting newspapers to cut aid spending, but announced last month that she would be renewing the 0.7% pledge. Diverting some of the money to other departments – such business, energy and industrial strategy – is seen as a way of blunting the attacks. The IFS said that despite criticism of aid being squandered, overseas assistance was the most heavily scrutinised part of government spending, with oversight from the International Development Committee, the National Audit Office and the Independent Commission for Aid Impact. Sonya Krutikova, an author of the IFS report, said: “The UK is now recognised internationally as leading on shaping the global development agenda and the Department for International Development scores highly on the international Aid Transparency Index. “A change of strategy since 2015 means that more emphasis is now put on using ODA spending for the UK’s national interest. There is clearly a trade-off between this, spending outside of ODA altogether, and ensuring the money is used most effectively for global poverty alleviation.”


Asia-Pacific tire market is projected to grow at a CAGR of over 8% during 2016-2021, driven by rising tire demand from OEM as well as replacement segments. Asia-Pacific is emerging as a hub for production of automobiles, with the automotive sector accounting for the largest private sector investment in research and development (R&D) in the region. During 2011-2015, demand for tires in the region grew on account growing automobile sales, expanding vehicle fleet size and increasing GNI per capita. Presence of major automotive OEMs such as Ford, Hyundai, Honda, Mahindra, Maruti Suzuki, TATA, BMW, etc., is propelling OEM tire demand in Asia-Pacific. Nevertheless, replacement segment continues to dominate demand for tires in the region due to continuing expansion of automobile fleet in Asia-Pacific. Passenger car and two-wheeler tire segments dominated tire demand in the region and the segments are anticipated to continue dominating tire demand in the country through 2021. Few of the leading global tire companies operating in Asia-Pacific tire market include Goodyear, Bridgestone, MRF, CEAT, Yokohama, Kumho, Hangzhou Zhongce, etc. Asia-Pacific Tire Market Forecast and Opportunities, 2021 report elaborates following aspects of tire market in Asia-Pacific: For more information about this report visit http://www.researchandmarkets.com/research/pg5bbd/apac_tire_market To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/asia-pacific-tire-market-forecast--opportunities-2021-rising-tire-demand-from-oem-as-well-as-replacement-segments---research-and-markets-300455114.html


The report "Liver Fibrosis - Pipeline Review, H1 2017" provides comprehensive information on the therapeutics under development for Liver Fibrosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Liver fibrosis is a scarring process which results in inflammation and liver cell death. Symptoms include abdominal pain, easy bruising, lack of appetite, nausea, tenderness and enlargement of the liver, weight loss and yellowing of skin and eyes. Risk factors include age, heavy alcohol consumption, and chronic infection with hepatitis B or C virus and weakened immune system. Liver Fibrosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Companies discussed in this report include  AdAlta Ltd, Advinus Therapeutics Ltd, Allergan Plc, Angion Biomedica Corp, Asubio Pharma Co Ltd, aTyr Pharma Inc, Beijing Kawin Technology Share-Holding Co Ltd, BioLineRx Ltd, Bioneer Corp, BiOrion Technologies BV, Bird Rock Bio Inc, Cellmid Ltd, ContraVir Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Dr. Falk Pharma GmbH, Dynavax Technologies Corp, Evotec AG, Galectin Therapeutics Inc, Genfit SA, GenKyoTex SA, GNI Group Ltd, HanAll Biopharma Co Ltd, HEC Pharm Co Ltd, Immuron Ltd, Intercept Pharmaceuticals Inc, INVENT Pharmaceuticals Inc, Isarna Therapeutics GmbH, KineMed Inc, Nitto Denko Corp, Pfizer Inc, Pharmaxis Ltd, Promedior Inc, Promethera Biosciences SA, ProMetic Life Sciences Inc, Ribomic Inc, RXi Pharmaceuticals Corp, Samumed LLC, Silence Therapeutics Plc, Sirnaomics Inc, TaiwanJ Pharmaceuticals Co Ltd, TCM Biotech International Corp, TRACON Pharmaceuticals Inc, Vascular Biogenics Ltd, Virobay Inc plc, and XTuit Pharmaceuticals Inc. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=966744 . (This report is available at upto 25% Discount till June 02nd 2017.) "Liver Fibrosis Global Clinical Trials Review, H2, 2016" provides an overview of Liver Fibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Liver Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.


The report "Liver Fibrosis - Pipeline Review, H1 2017" provides comprehensive information on the therapeutics under development for Liver Fibrosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Liver fibrosis is a scarring process which results in inflammation and liver cell death. Symptoms include abdominal pain, easy bruising, lack of appetite, nausea, tenderness and enlargement of the liver, weight loss and yellowing of skin and eyes. Risk factors include age, heavy alcohol consumption, and chronic infection with hepatitis B or C virus and weakened immune system. Liver Fibrosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Companies discussed in this report include  AdAlta Ltd, Advinus Therapeutics Ltd, Allergan Plc, Angion Biomedica Corp, Asubio Pharma Co Ltd, aTyr Pharma Inc, Beijing Kawin Technology Share-Holding Co Ltd, BioLineRx Ltd, Bioneer Corp, BiOrion Technologies BV, Bird Rock Bio Inc, Cellmid Ltd, ContraVir Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Dr. Falk Pharma GmbH, Dynavax Technologies Corp, Evotec AG, Galectin Therapeutics Inc, Genfit SA, GenKyoTex SA, GNI Group Ltd, HanAll Biopharma Co Ltd, HEC Pharm Co Ltd, Immuron Ltd, Intercept Pharmaceuticals Inc, INVENT Pharmaceuticals Inc, Isarna Therapeutics GmbH, KineMed Inc, Nitto Denko Corp, Pfizer Inc, Pharmaxis Ltd, Promedior Inc, Promethera Biosciences SA, ProMetic Life Sciences Inc, Ribomic Inc, RXi Pharmaceuticals Corp, Samumed LLC, Silence Therapeutics Plc, Sirnaomics Inc, TaiwanJ Pharmaceuticals Co Ltd, TCM Biotech International Corp, TRACON Pharmaceuticals Inc, Vascular Biogenics Ltd, Virobay Inc plc, and XTuit Pharmaceuticals Inc. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=966744 . (This report is available at upto 25% Discount till June 02nd 2017.) "Liver Fibrosis Global Clinical Trials Review, H2, 2016" provides an overview of Liver Fibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Liver Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Loading GNI Ltd. collaborators
Loading GNI Ltd. collaborators